MELANOMA

This study tested a new RNA cancer vaccine in 119 people with advanced melanoma. The vaccine was designed to train the immune system to attack four proteins found on melanoma cells. The main goal was to check the vaccine's safety and find the best dose, while also looking for sig…

This study tested a personalized vaccine made from each patient's own melanoma mutations. The goal was to see if it is safe and possible to create such a vaccine. Fifteen people with advanced melanoma received the vaccine, and researchers checked for side effects and immune respo…

This early-stage trial tested a custom-made vaccine called WDVAX in 23 people with advanced melanoma. The vaccine is created from each patient's own killed tumor cells, mixed with immune-boosting proteins, and formed into a small dissolvable tablet. The goal was to see if it's sa…

This phase II trial tests whether giving two targeted drugs (dabrafenib and trametinib) before and after surgery can improve outcomes for people with stage IIIB-C melanoma that has a BRAF V600 mutation. 35 participants will take the drugs for 12 weeks before surgery, then continu…

This study tested a new approach for people with advanced melanoma that can be surgically removed. Participants received a combination of two immunotherapies: one injected directly into the tumor (Tavo) and one given through a vein (nivolumab). After 12 weeks, they had surgery to…

This early-phase trial tested an experimental drug called KVA12123, given alone or with the immunotherapy Keytruda, in 40 adults with advanced solid tumors (like lung, breast, or colon cancer) that had stopped responding to standard treatments. The main goals were to check safety…

This early-phase study tested a personalized cancer vaccine (RO7198457) in 273 patients with advanced solid tumors like melanoma, lung, and breast cancer. The vaccine was given alone or with an immunotherapy drug (atezolizumab) to see if it was safe and how the body responded. Th…

This Phase 2 trial tested whether adding bosentan, a drug used for blood vessel conditions, to standard chemotherapy (dacarbazine) could slow tumor growth in people with stage IV melanoma. The study enrolled 80 adults with advanced melanoma and compared the combination to chemoth…

This study looked at 216 people with advanced melanoma that had stopped responding to standard treatments. Researchers tested each person's tumor for specific genetic changes and then gave them a drug designed to target that change. The goal was to see if this personalized approa…

This study tested whether adding other treatments to the drug pembrolizumab can help people with advanced melanoma that hasn't been treated before. Researchers checked safety and how many people's tumors shrank or disappeared. The trial involved 335 participants and was part of a…

This study tested a new drug called XTX202 in 95 people with advanced solid tumors that had not responded to standard treatments. The goal was to check safety, find the right dose, and see if the drug could shrink tumors. The trial is now complete.

This early-stage trial tested a new drug called AZD6244 combined with standard chemotherapies in 140 people with advanced solid tumors (breast, colon, lung, melanoma, kidney). The main goal was to see if the combination is safe and tolerable, and to find the best dose. Researcher…

This early-phase study tested a single dose of an experimental antibody (MEDI0562) given before surgery to 13 patients with advanced head and neck cancer or melanoma. The goal was to see if the drug safely activates the immune system to fight the cancer. Researchers compared givi…

This early-phase study tested a new drug called CCT3833 in 31 adults with advanced solid tumours, including melanoma. The main goal was to find a safe dose and check for side effects. Researchers measured how the drug moves through the body and looked for the best dose to use in …

This early-stage study tested a custom-made yeast vaccine designed to train the immune system to recognize and attack leftover cancer cells. Five adults with various cancers (like colorectal, breast, or lung) who had completed initial treatment received the vaccine. The goal was …

This study tested whether taking two targeted drugs (dabrafenib and trametinib) for 12 months after melanoma surgery could keep the cancer from returning. It included 870 adults with high-risk stage III melanoma that had a specific BRAF V600 mutation. Results showed the drug comb…

This early-stage trial tested an experimental drug called CTX-471, given alone or with the approved drug Keytruda, in 100 adults with advanced cancers like lung cancer, melanoma, and head and neck cancer. The goal was to see if the combination is safe and tolerable for patients w…

This study tested an experimental drug called BMS-986016 (anti-LAG-3) alone or combined with nivolumab in people with advanced solid tumors that had spread or couldn't be removed by surgery. It included several cancer types like lung, stomach, liver, kidney, bladder, head and nec…

This early-phase study tested a new drug called BAT4706 in 28 adults with advanced solid tumors or melanoma who had no other good treatment options. The main goal was to find a safe dose and check for side effects. This was not a cure study; it aimed to gather safety information …

This early-phase study tested whether adding a TNF-blocking drug (infliximab or certolizumab) to standard immunotherapy (nivolumab and ipilimumab) is safe for people with advanced melanoma that has spread. The main goal was to find the best dose and check for serious side effects…

This study tested whether adding denosumab (a bone-strengthening drug) to standard immunotherapy (pembrolizumab or nivolumab) could help control advanced melanoma that has spread. Researchers enrolled 25 adults with stage III or IV melanoma who had not received prior immunotherap…

This phase 3 trial tested whether ABP 206, a biosimilar to the cancer drug nivolumab (Opdivo), works similarly in people with advanced melanoma that has been surgically removed. 256 participants received either ABP 206 or Opdivo every 4 weeks for a year. The goal was to see if th…

This study tested whether combining two drugs, brentuximab vedotin and pembrolizumab, can shrink tumors in people with advanced melanoma, lung cancer, or head and neck cancer that has spread. About 161 adults took part. The main goal was to see how many patients had their tumors …

This phase 3 trial tested a combination of two targeted drugs, LGX818 and MEK162, against standard treatments in 921 people with advanced melanoma that has a BRAF V600 mutation. The study compared the combo to vemurafenib alone or LGX818 alone to see which worked better at delayi…

This early-phase trial tested a combination of two oral drugs, trametinib and ceritinib, in 27 people with advanced melanoma that had stopped responding to prior treatments. The main goals were to find a safe dose and see if the combination could shrink tumors. The study is compl…

This study tested an experimental drug (BMS-986253) combined with standard immunotherapy drugs (nivolumab with or without ipilimumab) in 281 people with advanced cancers like melanoma. The main goals were to check safety and see if tumors shrank. This is a disease-control approac…

This study tested a new way to do stem cell transplants in 23 children with cancers that came back or didn't respond to treatment. The method removes certain immune cells from the donor's stem cells to help the child's body recover faster and fight infections better. The goal was…

This study tested two different doses of an experimental drug called RO7247669 in 93 people with advanced melanoma that had not been treated before. The goal was to see how well the drug controls the cancer and to find the best dose with the fewest side effects. Participants rece…

This early-phase study tested whether genetically modified T-cells (MAGE-A10ᶜ⁷⁹⁶T) are safe for people with advanced urothelial cancer, melanoma, or head and neck cancer. Ten participants received their own engineered immune cells after chemotherapy. The main goal was to check fo…

This early-stage study tested an experimental drug called PLX3397 in 6 people with advanced melanoma that has a specific KIT gene mutation and cannot be removed by surgery. The goal was to check the drug's safety and see if it could shrink tumors. While some patients had their tu…

This early-phase study tested a combination of two experimental drugs (BGB-283 and PD-0325901) in 91 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and see if the drugs could shrink tumors. The trial is no…

This early-phase trial tested a new drug called NB003 in 258 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check the drug's safety, find the right dose, and see if it could shrink tumors. The study is now complete, an…

This trial tested a new treatment called GC101 TIL for people with advanced melanoma that has not responded to standard therapies. The treatment uses immune cells taken from the patient's own tumor, grown in a lab, and then given back to the patient. The study enrolled 18 partici…

This early-phase trial tested a personalized immunotherapy for people with advanced solid tumors. Doctors removed a sample of each patient's tumor, grew the immune cells (TILs) in a lab, and then infused them back along with another drug. The goal was to see if this approach is s…

This phase 2 trial tested a combination of two drugs—BO-112, injected directly into tumors, and pembrolizumab, given through a vein—in 42 adults with advanced melanoma that had stopped responding to standard immunotherapy. The goal was to see if the combo could shrink tumors and …

This early-phase trial tested a new way to treat advanced cancers that have spread. It combined a special type of radiation with two immunotherapy drugs (MEDI4736 and tremelimumab) to see if the combination is safe and tolerable. The study included 53 adults with advanced melanom…

This early-stage trial tested a new drug called CFT1946, alone or with other drugs, in 89 adults with solid tumors that have a BRAF V600 mutation, including melanoma, lung, colon, and thyroid cancers. The main goals were to check safety and find the best dose. The study is comple…

This study tested giving the cancer drug nivolumab as a shot under the skin (instead of through an IV) to people with advanced cancers like lung, kidney, melanoma, liver, and colorectal cancer. The main goal was to see how the drug moves in the body and to check for side effects.…

This study tested an experimental drug called BDB001 in people with advanced solid tumors (like skin, lung, or kidney cancer) that had stopped responding to standard immunotherapy. The goal was to see if BDB001 could shrink tumors or slow their growth. Only one person took part, …

This study tested several combinations of the immunotherapy drug pembrolizumab (Keytruda) with other experimental drugs in people with stage III melanoma that can be surgically removed. The goal was to see if these combinations are safe and more effective than current treatments …

This study tested a combination of an oral bacterial product (VE800) and the immunotherapy drug nivolumab in 56 people with advanced or metastatic cancers like melanoma, stomach, and colorectal cancer. The goal was to see if the bacteria could help the immune system fight tumors …

This early-phase trial tested a new approach for people with advanced melanoma that cannot be removed by surgery. The treatment combines a gene therapy injected directly into tumors with an oral drug that activates the therapy. The goal was to see if the combination is safe and t…

This completed phase 1/2 trial tested the safety and effectiveness of pembrolizumab (Keytruda) alone or combined with other drugs (quavonlimab or lenvatinib) in 56 people with melanoma that had spread to the brain. Participants had not received steroids recently and were neurolog…

This study tested a new drug called E7386 combined with the immunotherapy pembrolizumab (Keytruda) in 89 people with advanced melanoma, colorectal cancer, or liver cancer. The goal was to see if the combination is safe and can shrink tumors. Some participants with liver cancer al…

This study tested whether adding vibostolimab to the standard immunotherapy pembrolizumab can better prevent melanoma from returning after surgery. About 1,600 people with high-risk stage II to IV melanoma took part. The goal was to see if the combination keeps cancer away longer…

This study tested a combination of three immunotherapy drugs (INCMGA00012, INCAGN02385, and INCAGN02390) in 61 people with advanced melanoma or other solid tumors that had stopped responding to standard treatments. The goal was to find the safest dose and see if the drugs could s…

This Phase 2 trial tested a modified polio virus called lerapolturev, alone or combined with an immunotherapy drug, in 27 adults with advanced melanoma that had stopped responding to standard PD-1 therapy. The virus was injected directly into tumors to trigger an immune attack. R…

This study tests a special SPECT imaging agent that seeks out a protein called LRRC15, found on many aggressive cancers like pancreatic, breast, lung, and brain tumors. The goal is to see if this scan can help doctors diagnose and stage these cancers more accurately. Healthy volu…

This study tested whether a simple breath test can predict if cancer patients will respond to immunotherapy drugs. Researchers used an electronic nose device to analyze breath samples from 190 patients with lung, melanoma, kidney, bladder, or head and neck cancers. The goal is to…

This study tested whether an artificial intelligence (AI) system can help detect melanoma, a dangerous form of skin cancer. Researchers took photos of suspicious skin spots from 105 adults using a smartphone camera and let the AI analyze them. They compared the AI's results to di…

This study tests a program called FLARE that teaches families how to protect children from the sun. It includes children ages 8 to 17 who have a parent who survived melanoma and who have had at least one sunburn in the past year. Families are randomly assigned to either the FLARE…

This completed study tested a school-based educational program to improve sun protection among 38 rural Utah high school students. The program included a 90-minute session with skin cancer education, a risk self-assessment, and creating a personal sun protection plan. Surveys mea…

This study tested whether breathing in lavender essential oil for 15 minutes before skin cancer surgery could reduce anxiety. Sixty-six adults with early-stage melanoma or other skin cancers took part. Researchers measured anxiety using questionnaires and vital signs like heart r…

This study examines the patient profiles and treatment patterns of adults with melanoma in Japan who were prescribed either dabrafenib with trametinib or encorafenib with binimetinib. Researchers are looking at data from 2012 to 2021 to understand patient characteristics and how …

This study watched 152 melanoma patients who had their tumors surgically removed and then started nivolumab as part of their normal care. Researchers tracked how long patients stayed cancer-free, whether the cancer spread, and overall survival. The goal was to see how well the dr…

This study tested whether a family history app can help doctors collect and use information about patients' family health risks. Over 600 adults aged 30-69 took part. The goal was to see if the app leads to better screening and genetic referrals for conditions like cancer, heart …

This completed study involved 116 people with advanced melanoma. Researchers aimed to create a platform that goes beyond standard genetic testing to deeply profile tumors using advanced molecular technologies. The goal was to discover new biomarkers and help doctors make better t…

This study involved 60 people with advanced melanoma who were already scheduled to receive immunotherapy drugs. Researchers collected blood samples and, when possible, tumor samples before and during treatment to look for biological markers that might predict whether the treatmen…

This completed study tested whether a new biomarker called 'mass response' can predict how well a cancer therapy will work. Researchers collected tumor cells from 72 patients with various cancers through fluid drainage or biopsies. The goal was to see if this biomarker could guid…

This study examined blood and tumor samples from 25 people with advanced melanoma who were starting standard pembrolizumab treatment. Researchers looked at T cells—key immune cells—to find patterns that might predict whether the therapy works. The goal is to better understand why…

This study looked at immune cells (T cells, NK cells, and macrophages) inside melanoma tumors from 217 patients. The goal was to understand how these cells affect the body's ability to fight the cancer and how chemotherapy might change them. It was an observational study, not a t…

This study followed 187 melanoma patients treated with IMLYGIC, a modified herpes virus that attacks cancer cells. Researchers tracked whether the virus spread to patients' close contacts or healthcare providers, and monitored long-term safety for up to 5 years. The goal was to u…

This small pilot study tested whether special PET scans (FLT PET/CT) could detect early signs that immunotherapy is working in people with advanced melanoma. Five participants received standard immunotherapy drugs (pembrolizumab or nivolumab) and had scans, blood tests, and tumor…

This completed trial tested an interactive survivorship program for adolescent and young adult cancer survivors. The program included a mobile app, telehealth support, and printed materials to help survivors access healthcare resources, improve self-management skills, and reduce …

This completed study from Memorial Sloan Kettering Cancer Center looked at how people with a close family member who had melanoma make decisions about sun protection. Researchers interviewed 94 participants and used an electronic diary to track daily behaviors like sunscreen use …

This study looked at 98 adults with cancers like melanoma and lung cancer who were starting immunotherapy. Researchers measured inflammatory markers in their blood to understand how the body reacts to these drugs. The goal was to find ways to better manage side effects from treat…

This study looked at whether giving a written sheet to melanoma patients, to pass on to their close relatives, helps those relatives get a skin exam from a doctor. 420 patients and their family members took part. The goal was to see if the written reminder works better than just …

This study tested a new blood test (liquid biopsy) to find cancer markers in 135 people with head and neck, lung, or skin cancer. The goal was to see if the blood test works as well as a standard tissue biopsy. The study did not provide treatment but aimed to improve how doctors …

This study looked at how well the combination of dabrafenib and trametinib works in real-life settings for people with high-risk stage III melanoma that has been completely removed by surgery. It included 39 adults in Turkey whose melanoma had a specific genetic mutation (V600E).…

This study looked at people with advanced solid tumors (like lung, bladder, or melanoma) who had been on immunotherapy for one year and whose disease was stable. Half stopped treatment and half continued. The goal was to see if stopping early affected how long until the cancer pr…

This completed study examined whether healthy skin near a melanoma tumor contains hidden cancer stem cells that might predict the disease's return. Researchers analyzed tissue from 226 people with early-stage melanoma to see if these cells are linked to 5-year survival. The goal …

This completed study looked at 100 adults with stage III melanoma that could be removed by surgery. Researchers compared two immunotherapy drug combinations given before surgery: nivolumab plus relatlimab versus nivolumab plus ipilimumab. The goal was to understand patient charac…